Introduction: Since human papillomavirus vaccine introduction, incidence rates of cervical pre-cancers have decreased; however, the vaccine’s impact on noncervical anogenital precancers has not been shown. These precancers are identified opportunistically and are not collected routinely by most cancer registries.
select cancer registries covering 27.8% of the U.S. population that required reporting of these pre-cancers. Trends in incidence rates were evaluated with Joinpoint regression. Analyses were conducted in 2020.
declined by 19.1% per year among females aged 15−29 years after human papillomavirus vaccine introduction. Compared with that in the prevaccine period when high-grade anal precancer rates were
increasing, anal precancer rates after human papillomavirus vaccine introduction were stable among females aged 15−29 years and among males aged 30−39 years. Among males aged 15−29 years, the rates increased over the entire period but less so after human papillomavirus vaccine introduction.
human papillomavirus vaccine, which is suggestive of the impact of the vaccine on noncervical human papillomavirus cancers.